Liraglutide

Will your health insurance cover weight-loss medications? It depends on several factors, including where you live

Retrieved on: 
Wednesday, May 8, 2024
EHB, FDA, Risk, Overweight, Diabetes, ACA, Weight loss, Confusion, Liraglutide, Type 2 diabetes, Family, Type 2, Patient, Health policy, Medicare, Cardiovascular disease, FAQ, Government, Marketplace, Health insurance

Minneapolis, MN, May 08, 2024 (GLOBE NEWSWIRE) -- Interest in medications prescribed for weight loss is skyrocketing, sparking consumer questions about whether health insurance covers these often expensive drugs.

Key Points: 
  • Minneapolis, MN, May 08, 2024 (GLOBE NEWSWIRE) -- Interest in medications prescribed for weight loss is skyrocketing, sparking consumer questions about whether health insurance covers these often expensive drugs.
  • Today, medicareresources.org explains that coverage depends largely on an individual’s health status, the type of coverage they have, and also where they live.
  • It will not cover the medications, which are also known as GLP-1 agonists, for weight loss alone.
  • These GLP-1 receptor agonists are covered by Medicare when they are prescribed to treat Type 2 diabetes: Mounjaro, Ozempic, Trulicity, Rybelsus and Victoza.

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 7, 2024
FDA, Carcinoma, CMO, Peripheral neuropathy, Investment, Safety, Pharmacokinetics, Rash, MMAE, Hand, Human, Tumor microenvironment, Liraglutide, ATM, IND, ASCO, Obesity, Patient, Cleavage, MUC, Annual general meeting, CSPC, CB1, Cervical cancer, Biotechnology, Therapy, Insulin resistance

Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024

Key Points: 
  • Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024
    NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
  • We look forward to CSPC’s presentation of updated data at the ASCO 2024 Annual Meeting.
  • During the quarter, we also continued to advance CRB-913 for the treatment of obesity and expect to dose the first patient in Q1 2025.
  • Updated data from this study will be presented by CSPC as a poster at the ASCO 2024 Annual Meeting on June 1, 2024.

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity

Retrieved on: 
Thursday, May 2, 2024
Biometrics, Radiology, Biotechnology, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Liraglutide, Multimedia, Obesity, Drug development, Incidence, Patient, Weight loss, Dietary supplement

Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period.

Key Points: 
  • Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period.
  • Participants were also assessed for the exploratory outcome of adverse muscle composition, defined as high muscle fat infiltration and low muscle volume z-score.
  • The study found that liraglutide significantly reduced muscle fat infiltration when compared to placebo.
  • Additionally, a weight-invariant assessment of muscle volume was performed using AMRA’s muscle volume z-score did not show a significant reduction comparing liraglutide to placebo (mean treatment difference adjusted for baseline muscle volume z-score was -0.08 standard deviations).

Global Weight Loss Drugs Markets Report 2023-2024 & 2029 - The Emergence of GLP-1 and GIP, Unmet Market Needs and Emerging Product Pipeline - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Health, Fitness & Nutrition, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Online, Conditional sentence, Market, Semaglutide, Sale, Investment, Social media, Injection, Weight gain, Huadong Medicine, Safety, Risk, Plasma protein binding, CDC, Underweight, Alli, OTC, Overweight, Eli Lilly, GSK plc, Diabetes, Weight loss, Research, Liraglutide, USFDA, Appetite, Success, Roche, Obesity, Culture, Novo Nordisk, Distribution, Patient, Powder, Metabolism, Marketing, GIP, Cancer, COVID-19, Pharmacy, Growth, Prevalence, Pharmaceutical industry

The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.

Key Points: 
  • The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.
  • The global weight loss drugs market is expected to grow at a CAGR of 49.85% over the years 2024-2029.
  • The weight loss drugs market in the Asia Pacific is expected to grow significantly during the forecasted period.
  • Offline distribution channels, comprising brick-and-mortar pharmacies, clinics, and healthcare facilities, dominated the global weight loss drugs market in 2023.

NABP Report Explores How Illegal Online Sellers Exploit Consumer Demand for Weight Loss Drugs

Retrieved on: 
Wednesday, April 24, 2024
Online, Government agency, Risk, Food, Crime, Insurance, Weight loss, Liraglutide, National Association, Obesity, Partnership, Type 2 diabetes, NABP, Organization, Pharmaceutical industry

Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk.

Key Points: 
  • Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk.
  • NABP's RogueRx Activity Report explores illegal activity that has followed the rise of injectable weight loss drugs.
  • Illegal online sellers are exploiting this demand by offering substandard and falsified GLP-1 agonists to vulnerable patients.
  • Learn how you can warn patients against illegal online sellers of GLP-1 agonists by reading the RogueRx Activity Report .

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
MUC, Human, Biotechnology, CSPC, Drug discovery, Carcinoma, Cervical cancer, Rash, Patient, MMAE, Tumor microenvironment, Peripheral neuropathy, IND, PH1b, Insulin resistance, Investment, Investigational New Drug, Therapy, CB1, ATM, Safety, Liraglutide, CMO, FDA, PD-1, Pharmaceutical industry

We expect to dose the first patient in our US Ph1 study in March 2024.

Key Points: 
  • We expect to dose the first patient in our US Ph1 study in March 2024.
  • For CRB-601, the FDA cleared our Investigational New Drug (“IND”) application in January 2024, and we expect to dose the first patient this summer.
  • The Company presented CRB-913 pre-clinical data at Obesity Week as an oral presentation and as a late breaking poster in October 2023.
  • The Company is currently conducting IND enabling studies and expects to file an IND in the fourth quarter of 2024.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Multimedia, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Fitness & Nutrition, Pharmaceutical, Clinical Trials, Poster, Weight loss, Pharmacokinetics, Human, Investigational New Drug, Obesity, Patient, IND, Fasting, Keystone, Myostatin, GDF11, Mouse, Rock, MPH, Food, SMA, Body composition, Immunoglobulin G, Nandi (Hinduism), Doctor of Philosophy, Liraglutide, ELISA, Dietary supplement

“These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.

Key Points: 
  • “These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.
  • “We believe that preserving lean muscle mass through our highly selective approach to myostatin inhibition in combination with GLP-1 RA therapy has the potential to transform the management of weight loss.
  • In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
  • SRK-439 also improved fat mass loss (–36.60% to –46.32% from baseline with semaglutide; –17.31% to –19.04% from baseline with liraglutide).

Slim Pickings: Finding Cost-Effective Obesity Solutions

Retrieved on: 
Monday, January 8, 2024
Quality of life, Motivation, ICER, Goldman Sachs, Glucagon, Vegetable, Gross domestic product, Overweight, Multimedia, Type 2, Dark Ages, Weight loss, Hypertension, Diet, BMI, Depression, Person, Insulin, Pancreas, Diabetes, Trial of the century, Research, Human, Eye, Obesity, Fertility, Deoxycholic acid, Behavior, Insurance, Absenteeism, Food, Type 2 diabetes, Patient, Liraglutide, Therapy, Urbanization, Automation, Dopamine, Exercise, Orlistat, Environment, Dietary supplement

NEW YORK, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the Middle Ages and Renaissance, a full figure was a symbol of status, indicating one's wealth, fertility and power in an environment of food scarcity. Today, it has a negative connotation. Faced with antiquity's unreliable resources, humans were hardwired to prioritize calorie-dense, energy-rich foods. To reinforce this behavior, evolution gave a boost of dopamine to big eaters; those who failed to feast during times of plenty might starve when food ran out. While abundant calorie consumption was an advantage in early societies, the ingrained drive to stock up is now a liability as access to food has become more reliable.

Key Points: 
  • Obesity presents many health risks, and expensive GLP-1 agonists have grabbed the limelight, but there are affordable and effective ways to address it.
  • While this behavior was a boon during times of food instability, constant consumption of energy dense nourishment now contributes to obesity.
  • Obesity not only increases health risks and reduces quality of life and mobility; but also produces a significant economic impact.
  • This requires alternative approaches and comprehensive efforts that combine cost-effective medications with diet and exercise to reduce excessive obesity rates.